Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Apotex Inc.
Apotex has decisively overcome Horizon’s patent infringement suit stemming from its launch of a generic version of the originator’s Pennsaid 2%.
Derided by largest shareholder Sarissa as ‘dawdling’ and ‘lackadaisical,’ the board at Amarin has come out fighting, saying that a strategy of growing its heart drug in Europe will pay dividends.
Several stakeholders across the off-patent industry, including trade groups and manufacturers, have encouraged the FDA to scrap its proposal to require companies to submit citizen petitions for requesting therapeutic equivalence evaluations for 505(b)(2) applications.
SK Capital announced agreement to acquire Apotex, saying it will invest to “support Apotex’s next phase of growth and continued innovation for patient affordability."
- Drug Delivery
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- ApoPharma, Inc.
- Apotex Australia
- Arrow Pharmaceuticals Pty Ltd.
- Arrow Remedies Private Limited
- Arrotex Australia Group Pty Ltd
- Aveva Drug Delivery Systems, Inc.